IMS global Rx sales
North American pharmaceutical sales growth was outpaced by all other markets in 2005, IMS Health reports. For the year, sales in North America grew 5.2% (to $265.7 bil.), compared to 7.1% growth in Europe (to $169.5 bil.), 6.8% growth in Japan (to $60.3 bil.), 18.5% growth in Latin America (to $24 bil.) and 11% growth in Africa and non-Japan Asia Pacific (to $46.4 bil.). Biologics as a sector grew 17.1% in 2005, bringing their total sales to $52.7 bil. Leading products in terms of sales were Pfizer's Lipitor (6.4% growth to $12.9 bil.), Sanofi-Aventis/Bristol-Myers Squibb's Plavix (16% growth to $5.9 bil.) and AstraZeneca's Nexium (16.7% growth to $5.7 bil.)...
You may also be interested in...
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.